GSK taps Royal Bank of Scotland chair Philip Hampton to lead its own board

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

GSK taps Royal Bank of Scotland chair Philip Hampton to lead its own board

It's official: GlaxoSmithKline ($GSK) tapped Royal Bank of Scotland chair Philip Hampton to take the reins as chairman. The choice comes as increasingly restive shareholders call for change at the drugmaker, plagued by corruption scandals and suffering from competition to its megablockbuster respiratory drug Advair. He'll join GSK's board Jan. 1, become deputy chair in April and move into Chairman Christopher Gent's seat in September 2015. Report

GlaxoSmithKline
Philip Hampton joined as chairman.


Kadmon
Sam Waksal will head the biotech as CEO.

Biotech

> Sam Waksal has appointed his brother, Harlan Waksal, as CEO of his new biotech venture, Kadmon. Waksal, once convicted in an insider trading scandal related to ImClone, a biotech he founded, was banned from serving as a director of a public company. He will serve instead as Kadmon's head of innovation, science and strategy. Story

Paul Stinson has been appointed BioAlberta's new president and CEO. Release

Dr. Adam Koppel has joined Trevena's ($TRVN) board of directors, replacing Christopher Mirabelli. Release

Merus Labs International's CEO, Elie Farah, stepped down from his spot at the helm, to be replaced by Barry Fishman in the interim. Release

Transgene appointed Eric Quéméneur as its executive VP of R&D. Release

Azita Nejad joined ReVance Therapeutics as VP of quality. Release

Avillion appointed Jarrod Longcor as its chief business officer. Release

BioLife Solutions brought on Jason Acker and Anthony Davies to join its scientific advisory board. Release

Avalanche Biotechnologies appointed Dr. Roman Rubio as senior VP and head of translational medicine. Release

Olivier Danos joined Biogen Idec ($BIIB) as its senior VP of gene therapy. Release

Ophthotech ($OPHT) named Michael Atieh as its executive VP and chief financial and business officer. Release

Protein Technologies hired Nate Cosper as its president and CEO. Release

Celladon appointed Scott Garrett as its VP of commercial planning. Release

ChemoCentryx ($CCXI) brought on Dr. Israel Charo as its senior VP of research. Release

Synageva Biopharma appointed Robert Bazemore as its chief operating officer. Release

Michel Bouvier will be the new scientific advisory board chairman at Domain Therapeutics. Release

RainDance Technologies named Fritz Eibel its senior VP of strategic marketing. Release

Cerebain Biotech brought on Miriam Weber Miller as its corporate vice president. Release

> Coherus BioSciences has appointed Mary Szela to its board of directors. Release

> Pfenex ($PFNX) has appointed Robin Campbell to its board of directors. Release

Pharma

 > Valeant Pharmaceuticals ($VRX)  has appointed Jeffrey Ubben as a director of the board. Release

Biotech IT

Medidata ($MDSO) has appointed Michael Capone as chief operating officer. Release

 

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.